insulin glulisine vs Insulin lispro (Lyumjev)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
Reported efficacy
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)
Result source: NCT00135057
Insulin lispro (Lyumjev)
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)
Result source: NCT03952143
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin glulisine | Insulin lispro (Lyumjev) |
|---|---|---|
| HbA1c, change | -0.5% vs -0.5%vs Insulin LisproNCT011942582 other results
| -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT032143801 other result
|
| Body weight, change (kg) | 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| —Not reported |
| HbA1c below 7% | 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
| —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT00135057 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00135057 | —Not reported |
HbA1c, change
- insulin glulisine
- -0.5% vs -0.5%vs Insulin LisproNCT01194258
2 other results
- -2.5% vs -2.1% NCT00384085
- -0.4% vs -0.1% NCT00360698
- Insulin lispro (Lyumjev)
- -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT03214380
1 other result
- -0.6% vs -0.6% NCT03952143
Body weight, change (kg)
- insulin glulisine
- 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 1.5 vs 1.6 NCT01194258
- Insulin lispro (Lyumjev)
- —Not reported
HbA1c below 7%
- insulin glulisine
- 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 51.1% vs 39.5% NCT00384085
- Insulin lispro (Lyumjev)
- —Not reported
Fasting plasma glucose, change
- insulin glulisine
- —Not posted · NCT00135057
- Insulin lispro (Lyumjev)
- —Not reported
3-point MACE (% with event)
- insulin glulisine
- —Not posted · NCT00135057
- Insulin lispro (Lyumjev)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin glulisine: 4 of 4 rows · Insulin lispro (Lyumjev): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin glulisine | Insulin lispro (Lyumjev) |
|---|---|---|
| Dropout rate | 23.5%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | —b NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | —b NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 11.9%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 6.5%Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence | 7.7%b NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.4% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%15 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%30 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%7 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%15 U NCT03305822 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination 0%LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 3 more resultsany infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence | b nasopharyngitis 14% upper respiratory tract infection 8% diarrhoea 3.3% NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 15 more resultsupper respiratory tract infection 5.3% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 injection site reaction 5.6% NCT03341312 · Phase 1 · registry result, not featured evidence injection site reaction 2.9% NCT03341312 · Phase 1 · registry result, not featured evidence 15 U headache 10% nausea 5% injection site reaction 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 30 U headache 14.6% injection site reaction 14.6% nausea 7.3% NCT03286751 · Phase 1 · registry result, not featured evidence 7 U headache 15% injection site reaction 2.5% nausea 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 15 U headache 5.3% vessel puncture site thrombosis 5.3% NCT03305822 · Phase 1 · registry result, not featured evidence 15 U infusion site pain 12% catheter site bruise 8% vessel puncture site bruise 8% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U injection site pain 11.5% application site erythema 7.7% catheter site bruise 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site pain 10.7% catheter site swelling 7.1% application site erythema 3.6% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site bruise 7.7% infusion site erythema 7.7% infusion site swelling 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence headache 6.7% back pain 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence back pain 0% headache 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence · combination thrombophlebitis 6.9% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence thrombophlebitis 10.3% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 14 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin glulisine
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Insulin lispro (Lyumjev)
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · Insulin lispro (Lyumjev)'s landscape